Results for Anticancer Drugs

1 - 10 of 16
Frank M. Balis, MD
Frank M. Balis

Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.

E-mail:
balisf [at] chop.edu

In The News: Allergies, Delivery Modes, and Feeding Methods; Genomic Profiling; Tagging CAR T Cells; ‘and the Award Goes to …’

Published on
Nov 15, 2019
in Cornerstone Blog
In the News
This week “In The News,” our scientists and their groundbreaking research appear in Newsweek, Cell Reports, and Molecular Therapy.

Snapshot Science: Can Boosting an Oncogene Make Cancer Cells More Vulnerable to Chemotherapy?

Published on
May 1, 2019
in Cornerstone Blog
Oncogene
Oncogenes such as MYC are notorious troublemakers that promote cancer. Previous research strategies have focused on finding ways to quiet down levels of MYC; however, basic scientists at Children’s Hospital of Philadelphia took the opposite approach.

In the News: Mitochondrial Gene Variance, Killing Cancer Cells, NICU Stress Effects, Visually Impaired Driver Safety

Published on
Mar 22, 2019
in Cornerstone Blog
CHOP Research In the News
In this week’s roundup, our researchers make impactful discoveries in genetics, cancer treatment, and more.

Antibody-drug conjugate shows efficacy against cell surface protein in neuroblastoma

Published on
Mar 13, 2019
in Press Releases
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to an antibody that targets a surface protein expressed in most childhood neuroblastomas, effectively killing cancer cells.

In the News: Weight and CHD, Tumor Biology, I-ACT Grant, Mitochondrial Disease Guidelines

Published on
Nov 3, 2017
in Cornerstone Blog
CHOP Research In the News
From new insights into brain tumor biology to building a network for pediatric trials, don't miss this week's research roundup.

Biology of Childhood Brain Tumor Subtypes Offers Clues to Precision Treatments

Published on
Oct 16, 2017
in Press Releases
CHOP Researchers Reveal Differences among Gene Fusions in Low-Grade Pediatric Brain Tumors

Psychology in Media Award, Targeted Cancer Drugs, Dermatology App, CHOP ROP Model, Beckwith-Wiedemann Conference

Published on
Jul 28, 2017
in Cornerstone Blog
CHOP Research In the News
From cancer drugs designed to match a child's specific molecular abnormality, to a phone app that can offer a dermatologic diagnosis quicker than an office visit, the future of children's healthcare is unfolding right before our eyes at the Children's Hospital of Philadelphia Research Institute.

Snapshot Science: Do Researchers Need Standardized Dosing for Infant Anticancer Drug Trials?

Published on
Jul 18, 2017
in Cornerstone Blog
infant anticancer drugs
Researchers from the Children's Oncology Group (COG) have developed a new standardized dosing method for anticancer drugs in infants to use across all COG clinical trials. This unified method, based on dose banding and organized into tables for different drugs and dose levels, will address the limitations and variability that researchers can encounter in current methods.

Why it matters:

Doses

Research on Crucial Cutting Enzyme Maps DNA Damage in Leukemias

Published on
Jun 15, 2017
in Press Releases
CHOP and Penn Researchers Map Detailed Sites of DNA Damage that Lead to Abnormal Genetic Rearrangements
1 - 10 of 16